TherapeuticsMD Inc (NASDAQ:TXMD) – Jefferies Group reduced their FY2020 earnings per share (EPS) estimates for shares of TherapeuticsMD in a note issued to investors on Tuesday. Jefferies Group analyst M. Andrews now anticipates that the company will post earnings of $0.29 per share for the year, down from their previous forecast of $0.34.

A number of other equities analysts also recently commented on the company. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 25th. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research note on Thursday, November 30th. Cowen reiterated an “outperform” rating and issued a $16.00 price target (up from $13.00) on shares of TherapeuticsMD in a research note on Monday, November 6th. Cantor Fitzgerald reiterated a “buy” rating and issued a $31.00 price target on shares of TherapeuticsMD in a research note on Wednesday, November 29th. Finally, Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. TherapeuticsMD currently has a consensus rating of “Buy” and an average target price of $14.50.

TherapeuticsMD (NASDAQ TXMD) traded down $0.10 during trading hours on Wednesday, reaching $5.38. The company had a trading volume of 1,010,900 shares, compared to its average volume of 1,807,370. The firm has a market capitalization of $1,160.00, a P/E ratio of -14.14 and a beta of 0.99. TherapeuticsMD has a fifty-two week low of $3.50 and a fifty-two week high of $8.30.

Hedge funds and other institutional investors have recently modified their holdings of the business. Candriam Luxembourg S.C.A. lifted its holdings in TherapeuticsMD by 10.4% in the third quarter. Candriam Luxembourg S.C.A. now owns 530,000 shares of the company’s stock worth $2,804,000 after acquiring an additional 50,000 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in TherapeuticsMD by 10.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after acquiring an additional 67,855 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in TherapeuticsMD by 26.6% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 142,930 shares of the company’s stock worth $756,000 after acquiring an additional 30,030 shares during the last quarter. Swiss National Bank lifted its holdings in TherapeuticsMD by 12.3% in the third quarter. Swiss National Bank now owns 289,800 shares of the company’s stock worth $1,533,000 after acquiring an additional 31,800 shares during the last quarter. Finally, State Street Corp lifted its holdings in TherapeuticsMD by 14.9% in the second quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after acquiring an additional 583,094 shares during the last quarter. 72.65% of the stock is currently owned by hedge funds and other institutional investors.

In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of the business’s stock in a transaction on Friday, December 8th. The shares were purchased at an average price of $6.21 per share, with a total value of $31,050.00. Following the completion of the acquisition, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $22,076.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 23.92% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/02/14/fy2020-eps-estimates-for-therapeuticsmd-inc-txmd-decreased-by-analyst.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.